CS
ARCT icon

Credit Suisse’s Arcturus Therapeutics ARCT Stock Holding History

Credit Suisse’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.25M Sell
36,987
-259
-0.7% -$9.18K ﹤0.01% 2132
2023
Q4 		$1.17M Sell
37,246
-7,607
-17% -$181K ﹤0.01% 2236
2023
Q3 		$1.15M Sell
44,853
-16,693
-27% -$514K ﹤0.01% 2215
2023
Q2 		$1.77M Buy
61,546
+18,571
+43% +$506K ﹤0.01% 1995
2023
Q1 		$1.03M Buy
42,975
+5,451
+15% +$97.8K ﹤0.01% 2309
2022
Q4 		$636K Buy
37,524
+4,437
+13% +$77.4K ﹤0.01% 2629
2022
Q3 		$490K Buy
33,087
+8,309
+34% +$139K ﹤0.01% 2790
2022
Q2 		$390K Sell
24,778
-863
-3% -$16.9K ﹤0.01% 3001
2022
Q1 		$692K Sell
25,641
-363
-1% -$9.26K ﹤0.01% 2784
2021
Q4 		$963K Buy
26,004
+1,433
+6% +$58.4K ﹤0.01% 3349
2021
Q3 		$1.17M Buy
24,571
+12,788
+109% +$573K ﹤0.01% 3210
2021
Q2 		$398K Sell
11,783
-2,919
-20% -$98.8K ﹤0.01% 3977
2021
Q1 		$607K Sell
14,702
-34,829
-70% -$2.08M ﹤0.01% 3643
2020
Q4 		$2.15M Sell
49,531
-26,030
-34% -$1.76M ﹤0.01% 2765
2020
Q3 		$3.24M Buy
75,561
+59,346
+366% +$2.95M ﹤0.01% 2068
2020
Q2 		$757K Sell
16,215
-3,144
-16% -$108K ﹤0.01% 3076
2020
Q1 		$263K Sell
19,359
-39,644
-67% -$507K ﹤0.01% 3502
2019
Q4 		$641K Buy
+59,003
New +$618K ﹤0.01% 3417
2017
Q1 		– Sell
-1,972
Closed -$29K – 3798
2016
Q4 		$29K Sell
1,972
-9,999
-84% -$149K ﹤0.01% 4053
2016
Q3 		$207K Buy
11,971
+3,388
+39% +$109K ﹤0.01% 3796
2016
Q2 		$270K Buy
8,583
+91
+1% +$2.87K ﹤0.01% 3743
2016
Q1 		$225K Buy
8,492
+2,243
+36% +$75.9K ﹤0.01% 3642
2015
Q4 		$275K Buy
+6,249
New +$281K ﹤0.01% 3730
2014
Q4 		– Sell
-7,860
Closed -$850K – 4575
2014
Q3 		$850K Buy
7,860
+5,997
+322% +$781K ﹤0.01% 3201
2014
Q2 		$226K Buy
1,863
+220
+13% +$26.6K ﹤0.01% 4282
2014
Q1 		$209K Buy
+1,643
New +$244K ﹤0.01% 4327

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Credit Suisse's ARCT Position: Q1 2024 in Review

Credit Suisse reduced its Arcturus Therapeutics (ARCT) stake by 0.7% in Q1 2024, selling an estimated $9.18K and leaving 36,987 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

Credit Suisse first reported a position in ARCT in Q1 2014 and has held it in 26 quarters since. The position peaked at $3.24M in Q3 2020. 179 funds tracked by Wall St. Rank hold ARCT as of Q1 2024.

  • Credit Suisse held 36,987 shares of Arcturus Therapeutics worth $1.25M as of Q1 2024.
  • Credit Suisse sold 259 Arcturus Therapeutics shares in Q1 2024, an estimated $9.18K.
  • Arcturus Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2132 holding.
  • Credit Suisse first reported a position in Arcturus Therapeutics in Q1 2014 and has held it in 26 quarters since.
  • Credit Suisse's Arcturus Therapeutics position peaked at $3.24M in Q3 2020.
  • 179 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.